Amendment

In the specification:

Page 3, line 24, after "07/800,474 filed 8/31/94," insert --now abandoned in favor of continuing application 08/151,568,--.

Page 3, line 29, after ""07/938,079 filed 11/26/91," insert --now abandoned in favor of continuing application 08/185,318,--.

Page 11, line 11, delete --U.S. Patent No. 4,879,263-- and insert therefor --a U.S. patent--.

In the claims:

Please amend the pending claims as follows:

1. (amended) A method to induce an antitumor immune response in a potential or actual prostate tumor-bearing subject which method comprises administering to said subject a composition comprising an [active] ingredient which is active to induce said immune response and is selected from the group consisting of

at least one antigen overrepresented in the prostate gland or an immunologically effective portion thereof;

an expression system capable of generating *in situ* said antigen; and

an antiidiotypic antibody or [fragment] an immunologically effective portion thereof which mimics said antigen.

2. (amended) The method of claim 1 wherein said antigen [in] is a protein or peptide.

3. (amended) The method of claim 2 wherein said protein or peptide is selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA, PAP] and [a fragment thereof] an immunologically effective portion thereof.

6. (amended) The method of claim 1 wherein said composition is administered to said subject [is in a "neoadjuvant" setting] prior to surgical excision of said prostate tumor.

8. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises [an active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration and is

an expression system capable of generating *in situ* an antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof.

9. (amended) The vaccine of claim 8 wherein said antigen is selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA, PAP] and [a] an immunologically effective portion thereof.

14. (amended) The vaccine of claim 8 wherein said expression system consists essentially of DNA encoding said antigen or said portion or wherein said expression system comprises a living expression vector.

15. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in subject which comprises [as active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration and is

an antiidiotypic antibody or [fragment] immunologically effective portion thereof which mimics an antigen overrepresented on the prostate gland with respect to other tissues [or an immunologically effective portion thereof].

16. (amended) The vaccine of claim 15 wherein said antigen is selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA, PAP] and [a] an immunologically effective portion thereof.

21. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises [as active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration and comprises

at least one antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof,

wherein said [active] ingredient is encapsulated in or coupled to a liposome.

22. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises at least two [active] ingredients which are active to elicit said immune

response and are formulated for parenteral administration, wherein each ingredient is selected from the group consisting of

an antigen overrepresented on the prostate gland with respect to other tissues or an immunologically effective portion thereof;

an expression system capable of generating *in situ* said antigen or said portion; and

an antiidiotypic antibody or [fragment] an immunologically effective portion thereof which mimics said antigen [or portion].

23. (amended) The vaccine of claim 22 wherein said antigen is selected from the group consisting of PSA, PSMA, PAP and [a] an immunologically effective portion thereof.

28. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors which comprises [as active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration, and comprises at least one immunologically effective portion of an antigen overrepresented on the prostate gland with respect to other tissues said portion being less than the complete antigen.

29. (amended) The vaccine of claim 28 wherein said antigen is selected from the group consisting of prostate specific antigen (PSA), prostate specific membrane antigen (PSMA), prostatic acid phosphatase (PAP) [PSA, PSMA, PAP].

30. (amended) The vaccine of claim 28 wherein [the] said portion is encapsulated in a liposome or coupled to a liposome.

34. (amended) A pharmaceutical or veterinary vaccine for eliciting an antitumor immune response to prostate tumors in a subject which comprises [as active] an ingredient which is active to elicit said immune response, is formulated for parenteral administration, and comprises at least one antigen overrepresented on the prostate gland with respect to other tissues with the proviso that said antigen is other than human prostate specific antigen (PSA) in a form which is produced in human cells.

36. (amended) The vaccine of claim 34 wherein said antigen is selected from the group consisting of PSA, PSMA, PAP and [a] an immunologically effective portion thereof.

Remarks

The specification and claims have been amended in response to the various objections and rejections. In particular, claims 8, 15, 21, 22, 28 and 34 have been amended to point out more clearly that the active ingredient is formulated for parenteral administration, and to spell out what the activity is. Support for these amendments is found on page 16, lines 1-18 and page 5, lines 28-30 as well as by the characterization of the active ingredient as an antigen which automatically implies that an immune response will be generated. Accordingly, no new matter has been added and entry of the amendment is respectfully requested.